1EXEL Stock Overview

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. More details

1EXEL fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	4/6
Past Performance	6/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 73.6% below our estimate of its fair value

Earnings are forecast to grow 18.74% per year

Earnings grew by 213.9% over the past year

Risk Analysis

Shares are highly illiquid

Significant insider selling over the past 3 months

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Exelixis, Inc. Competitors

Philogen

BIT:PHIL

€922.6m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.4b

Swedish Orphan Biovitrum

OM:SOBI

SEK 102.1b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$11.5b

Price History & Performance

Summary of share price highs, lows and changes for Exelixis
Historical stock prices
Current Share Price	US$39.28
52 Week High	US$39.33
52 Week Low	US$35.70
Beta	0.25
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	19.46%

Recent updates

Shareholder Returns

	1EXEL	IT Biotechs	IT Market
7D	20.6%	-5.3%	4.3%
1Y	n/a	-4.6%	13.1%

Return vs Industry: Insufficient data to determine how 1EXEL performed against the Italian Biotechs industry.

Return vs Market: Insufficient data to determine how 1EXEL performed against the Italian Market.

Price Volatility

Is 1EXEL's price volatile compared to industry and market?
1EXEL volatility
1EXEL Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.4%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.8%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1EXEL's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1EXEL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1994	1,147	Mike Morrissey	www.exelixis.com

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Exelixis, Inc. Fundamentals Summary

How do Exelixis's earnings and revenue compare to its market cap?
1EXEL fundamental statistics
Market cap	€9.02b
Earnings (TTM)	€576.25m
Revenue (TTM)	€2.06b

18.9x

P/E Ratio

5.3x

P/S Ratio

Is 1EXEL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1EXEL income statement (TTM)
Revenue	US$2.30b
Cost of Revenue	US$74.13m
Gross Profit	US$2.22b
Other Expenses	US$1.58b
Earnings	US$643.57m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	2.36
Gross Margin	96.78%
Net Profit Margin	27.99%
Debt/Equity Ratio	0%

How did 1EXEL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/14 00:55
End of Day Share Price	2025/05/14 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exelixis, Inc. is covered by 41 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ishan Majumdar	Baptista Research
Peter Lawson	Barclays
Jason Matthew Gerberry	BofA Global Research

Exelixis BIT:1EXEL Stock Report